Trial reportDiabetes technology & therapeutics2018
Performance of the Omnipod Personalized Model Predictive Control Algorithm with Meal Bolus Challenges in Adults with Type 1 Diabetes.
Trial report in Diabetes technology & therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G.Diabetes technology & therapeutics · 2022Trial
- A Randomized, Placebo-Controlled Double-Blind Trial of a Closed-Loop Glucagon System for Postbariatric Hypoglycemia.The Journal of clinical endocrinology and metabolism · 2020Trial
- Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions.Diabetes technology & therapeutics · 2020Trial
- Safety, efficacy and psychological impact of Omnipod hybrid closed loop system in children, adolescents, and adults in 24 h and nighttime: Systematic review with additional meta-analysis.Journal of diabetes and metabolic disorders · 2025Review
- 7. Diabetes Technology: Standards of Care in Diabetes-2025.Diabetes care · 2025Review
- 7. Diabetes Technology: Standards of Care in Diabetes-2024.Diabetes care · 2024Review
- Real-World User and Clinician Perspective and Experience with MiniMed™ 780G Advanced Hybrid Closed Loop System.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- 7. Diabetes Technology: Standards of Care in Diabetes-2023.Diabetes care · 2023Review
- Clinical Implementation of the Omnipod 5 Automated Insulin Delivery System: Key Considerations for Training and Onboarding People With Diabetes.Clinical diabetes : a publication of the American Diabetes Association · 2022Article
- Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence.Diabetes & metabolism journal · 2021Review
- Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes.Diabetes care · 2021Article
- Prospective Independent Evaluation of the Carbohydrate Counting Accuracy of Two Smartphone Applications.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021Article
- First Outpatient Evaluation of a Tubeless Automated Insulin Delivery System with Customizable Glucose Targets in Children and Adults with Type 1 Diabetes.Diabetes technology & therapeutics · 2021Article
- Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives.Reviews in endocrine & metabolic disorders · 2021Review
- Review of the OmnipodTherapeutic delivery · 2020Review
- Automated Insulin Delivery in Adults.Endocrinology and metabolism clinics of North America · 2020Review
- MiniMed 670G hybrid closed loop artificial pancreas system for the treatment of type 1 diabetes mellitus: overview of its safety and efficacy.Expert review of medical devices · 2019Review
- A Clinical Guide to Advanced Diabetes Devices and Closed-Loop Systems Using the CARES Paradigm.Diabetes technology & therapeutics · 2019Article
- A Clinical Overview of Insulin Pump Therapy for the Management of Diabetes: Past, Present, and Future of Intensive Therapy.Diabetes spectrum : a publication of the American Diabetes Association · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study assessed the safety and performance of the Omnipod MATERIALS AND
methodsA supervised 54-h hybrid closed-loop (HCL) study was conducted in a hotel setting after a 7-day outpatient open-loop run-in phase. Adults aged 18-65 years with type 1 diabetes and HbA1c 6.0%-10.0% were eligible. Primary endpoints were percentage time in hypoglycemia <70 mg/dL and hyperglycemia ≥250 mg/dL. Glycemic responses for 4 h to a 130% overestimated bolus and a missed meal bolus were compared with a 100% bolus for identical meals, respectively. The 12-h postprandial responses to a high-fat meal were compared using either a standard or extended bolus.
resultsTwelve subjects participated in the study, with (mean ± standard deviation): age 35.4 ± 14.1 years, diabetes duration 16.5 ± 9.3 years, HbA1c 7.7 ± 0.9%, and total daily dose 0.58 ± 0.19 U/kg. Outcomes for the 54-h HCL period were mean glucose 153 ± 15 mg/dL, percentage time <70 mg/dL [median (interquartile range)]: 0.0% (0.0-1.2%), 70-180 mg/dL: 76.1% ± 8.0%, and ≥250 mg/dL: 4.5% ± 3.6%. After both the 100% and 130% boluses, postprandial percentage time <70 mg/dL was 0.0% (0.0-0.0%) (P = 0.50). After the 100% and missed boluses, postprandial percentage time ≥250 mg/dL was 0.2% ± 0.6% and 10.3% ± 16.5%, respectively (P = 0.06). Postprandial percentages time ≥250 mg/dL and <70 mg/dL were similar with standard or extended boluses for a high-fat meal.
conclusionsThe Omnipod personalized MPC algorithm performed well and was safe during day and night use in response to overestimated, missed, and extended meal boluses in adults with type 1 diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.